Although ketamine clinics may provide a roadmap for psilocybin clinics, a key difference is that psilocybin remains a Schedule I drug under the Controlled Substances Act.
The FDA has continually reiterated its position that CBD products cannot be marketed for therapeutic or medical uses without having been reviewed for safety and effectiveness.
This is welcome news for farmers generally as agricultural-related businesses have not yet been able to apply for Economic Injury Disaster Loans (EIDL) offered under the CARES Act.